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Critically ill patients have abnormal circadian and sleep homeostasis. This may be associated with higher morbidity and mortality.
The aims of this pilot studywere (1) to describemelatonin secretion in conscious critically illmechanically ventilated patients and (2)
to describe whether melatonin secretion and sleep patterns differed in these patients with and without remifentanil infusion. Eight
patients were included. Blood-melatonin was taken every 4th hour, and polysomnography was carried out continually during a 48-
hour period. American Academy of Sleep Medicine criteria were used for sleep scoring if sleep patterns were identified; otherwise,
Watson’s classification was applied. As remifentanil was periodically administered during the study, its effect on melatonin and
sleep was assessed. Melatonin secretion in these patients followed a phase-delayed diurnal curve. We did not observe any effect
of remifentanil on melatonin secretion. We found that the risk of atypical sleep compared to normal sleep was significantly lower
(𝑝 < 0.001) under remifentanil infusion. Rapid Eye Movement (REM) sleep was only observed during the nonsedation period. We
found preserved diurnal pattern of melatonin secretion in these patients. Remifentanil did not affect melatonin secretion but was
associated with lower risk of atypical sleep pattern. REM sleep was only registered during the period of nonsedation.
1. Introduction
Disturbances in sleep and circadian rhythm in critically
ill patients have been in focus during recent years due to
potential association of disrupted sleep with delirium and
increased morbidity and mortality in this patient group.
Critically ill patients are exposed to a range of factors
that may affect the brain structures responsible for the main-
tenance of circadian and sleep homeostasis: the brain stem,
hypothalamus, and thalamus. Morbidities and medication,
for instance, sedative agents, are among the important fac-
tors.
Melatonin is the hormone secreted by the pineal gland,
located in epithalamus, under control of the suprachiasmatic
nucleus. Melatonin takes part in the regulation of sleep and
circadian rhythm. Detection of melatonin levels in serum or
saliva or melatonin-derivate 6-sulfatoxymelatonin (6-SMT)
in urine is used to estimate melatonin secretion pattern.
Melatonin secretion in critically ill patients has been
investigated in several studies reporting conflicting results.
Some studies reported abolished melatonin secretion pattern
in sedated critically ill patients [1–3], while preserved circa-
dian periodicity ofmelatonin secretion in critically ill patients
with [4] or without [2] sedationwas reported in other studies.
The gold standard for sleep monitoring, allowing for the
description of sleep patterns, is polysomnography.
Previous polysomnographic sleep studies in intensive
care unit (ICU) have shown severely abnormal sleep patterns.
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Opioid agents (e.g., fentanyl), which are often used for
sedation in critically ill patients, have been shown to reduce
restorative sleep [5]. However, no polysomnographic studies
have been done to show the effect of remifentanil, the
ultrashort acting synthetic opioid, used for analgosedation,
on sleep pattern in critically ill patients.
In this pilot descriptive study we aimed (1) to describe
melatonin secretion pattern in conscious critically ill patients
on mechanical ventilation and (2) to describe whether
melatonin secretion and sleep patterns as determined by
PSG differed in these patients with and without remifentanil
infusion. Remifentanil is a standard drug of choice for
analgosedation in the ICU, where the study was carried out.
2. Materials and Methods
This pilot study was conducted in a mixed 8-bed Intensive
Care Unit at Vejle Hospital, Denmark. It was approved by
the Regional Ethics Committee of Southern Denmark (S-
20120001). The patients included in the study were a part of
the “Sleep in ICU” project, registered with ClinicalTrials.gov
(NCT01681043).
Conscious critically ill adults with expected duration of
mechanical ventilation ≥ 48 hours were eligible for the study.
The exclusion criteria were coma, delirium at inclusion, acute
clinical signs of intracerebral events, and circulatory shock.
Eligible patients were informed about the project by themain
investigator and included in the study after informed consent.
The patients had an arterial catheter routinely inserted
at admission to the ICU. Blood samples from this catheter
were taken in 8 patients every 4th hour in a 48-hour period
to assess S-melatonin. Enzyme-linked immunosorbent assay
(ELISA) method was used for melatonin analysis, using
ELISA kit provided by IBL international [6].
PSG monitoring included recording of electroencepha-
lography (EEG), bilateral electrooculography, and submental
electromyography according to the worldwide accepted stan-
dard of American Academy of Sleep Medicine (AASM) for
polysomnographic sleepmeasurement.The EEG consisted of
frontal (F3-A2, F4-A1), central (C3-A2, C4-A1), and occip-
ital (O1-A2, O2-A1) channels and was recorded using the
EEG and Sleep Recorder Trackit (Lifelines Ltd., UK). The
electrodes were applied by the main investigator during the
first day of participation. All PSGs consisted of 30 sec epochs
and were manually assessed by an expert in sleep medicine.
Standard AASM sleep assessment criteria could not be used
alone due to abnormal patterns in many of the recordings.
Accordingly, the modified sleep scoring classification for
critically ill patients suggested by Watson et al. was applied
[7]. Behavioral aspect of Watson’s classification was not used
because the recordings were reviewed later.
3. Statistical Analysis
Log transformation was used for normalizing the data. A
random effects linear regression model was used to assess
the effects of remifentanil (as a categorical variable), age,
sex, and Sequential Organ Failure Assessment (SOFA) score
[8] upon the melatonin secretion. Trigonometric terms were
included to account for the diurnal harmonic variation.
Inhomogeneity between patients was accounted for by using
patients’ id as a random effect. Insignificant effects were
removed one at a time, followed by a reestimation. Effects
with 𝑝 values < 0.05 were considered significant. Graphs of
the observed data, plotted against time, suggested that the
level of melatonin had a diurnal variation in the form of a
harmonic curve. By fundamental trigonometric lows, such
a curve can be achieved by a sum of a sine and a cosine
term: 𝑎 ∗ sin(𝑥) + 𝑏 ∗ cos(𝑥), where 𝑎 and 𝑏 determine
the time of nadir/acrophase as well as the amplitude of the
curve. We entered gender-specific sin(time) and cos(time)
terms in the regression. The estimated coefficients were
subsequently used to calculate gender-specific estimates of
time for nadir/acrophase and amplitude.
The recorded PSG epochswere classified into four groups:
normal sleep (scored according to AASM standard), atypical
sleep (Watson’s classification), awake, and undefined (the
epochs with artefacts). A multinomial regression model
with random effects, including remifentanil (as a categorical
variable), sex, and age as covariates, was used for testing
the association between remifentanil infusion and the four
sleep/wake conditions.
Normal sleep and atypical sleep groups were plotted as
the proportions of sleep (normal sleep + atypical sleep +
wake + undefined = 100%) over the 24-hour period
together with melatonin to visualize diurnal variation of
sleep and melatonin. Melatonin line represents connected
mean melatonin values at each sample point (six sam-
ple points with 4 hour intervals), and these values were
standardized to sleep proportion values to visualize both
curves on the same scale on 𝑦-axis so that melatoninstd =
(melatonin/max(melatonin)) ×max(sleep,%).
STATA, version 13 and 14, was used as statistical software
[9].
4. Results
Eight conscious, critically ill patients on mechanical venti-
lation and being able to give consent were included in the
study. Data collection proceeded from September 2012 until
November 2013. Patient baseline characteristics are presented
in Table 1.
Remifentanil infusion was applied as analgosedation in
6 patients, dose of 0.06 to 0.360mg/hour, either during the
whole period of participation or episodically after decision
of an intensivist doctor in charge. Remifentanil was infused
during 43% of the total time of participation, while no
continuous sedation was given during the rest (57%) of the
time.
The analysis of melatonin secretion showed that criti-
cally ill patients followed a diurnal harmonic curve, phase-
delayed compared with the physiological norm pattern of
melatonin secretion [10] with acrophase at approximately
4:30 am and nadir at approximately 4:30 pm (Figure 1). The
interindividual variation and the interday variation within
individuals contributedwith 64%and 10%, respectively, of the
total random variation. Figure 2 gives the diurnal variation
of melatonin by patients for both days (individual melatonin
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Table 1: Patient baseline characteristics, 𝑛 = 8.
Age, years, median (min; max) 70 (62; 85)
Sex Female: 5, Male: 3
APACHE II1, median (min; max) 24 (21; 33)
SOFA2, median (min; max) 3 (2; 5)
RASS score3 (range) −1 to +1
Length of ICU stay before the inclusion,
days, median (min; max) 2.5 (1; 10)
Admission diagnosis (%)
Pneumonia 3 (40%)
Chronic obstructive pulmonary disease 3 (40%)
Sepsis/respiratory distress 1 (10%)
Neurologic disease 1 (10%)
1APACHE II: Acute Physiology and Chronic Health Evaluation II (severity
of disease classification system).
2SOFA score: Sequential Organ Failure Assessment score.
3RASS-score: Richmond Agitation-Sedation Scale score.
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Figure 1: Diurnal variation ofmelatonin by gender.Meanmelatonin
values, ng/L; the grey field represents confidence intervals.
profiles). The log-scale was found to normalize the data, and
it is on this scale that data allow for appreciation of both
interindividual and diurnal variation patterns. On the orig-
inal scale the dominant interindividual variation eliminates
the diurnal variation for patients at low levels of melatonin.
A borderline significant effect of sex (𝑝 = 0.06) was found on
melatonin secretion pattern. Remifentanil infusion was not
significantly associated with the melatonin secretion pattern,
whereas the diurnal variation was significant.
Diurnal variation ofmelatonin and sleep (%normal sleep,
scored according to AASM standard, and % atypical sleep,
scored according to Watson’s classification) are presented in
Figure 3.
The analysis of association of remifentanil analgosedation
and sleep patterns showed that remifentanil infusion affected
the balance between the four groups (normal sleep, atypical
sleep, wake, and undefined) significantly but in different
manners for males and females (Figure 4). Furthermore,
there was a strong age effect, which also varied between
genders and between remifentanil infusion and noninfu-
sion.
Use of remifentanil infusion was associated with the
reduced proportion of atypical sleep for females at all ages,
with a slight increase at increasing ages. Females of age < 70
years increased their proportion of normal sleep and females
at all ages increased their proportion at wake condition.
Remifentanil infusion was associated with a significant
reduction of atypical sleep inmales as well, but at a lower level
compared with females. The proportion of time being awake
was reduced for males < 70 years but increasing with age to
higher level relative to not being under remifentanil infusion.
Themost notable effect was a large increase in the proportion
of normal sleep, in particular for males < 70 years, starting at
85% at age 68 and declining to 10% for males aged 85.
REM sleep was only observed in the PSG recordings
during the period without remifentanil in two patients
(4.5min and 10.5min, resp.).
Atypical stages 1 and 2, scored in accordance with Wat-
son’s modified sleep scoring classification for critically ill
patients [7] (presence of alfa or theta activity and delta activ-
ity), were registered with or without remifentanil infusion,
while atypical stages 3–5 (polymorphic delta activity without
alfa or beta activity, burst-suppression pattern, or suppressed
EEG pattern) were only observed during remifentanil infu-
sion.
5. Discussion
The main findings of this pilot descriptive study were as
follows:
(i) melatonin secretion pattern in conscious, critically ill
mechanically ventilated patients followed a harmonic
sinusoid diurnal but phase-delayed curve;
(ii) no association of remifentanil infusion with mela-
tonin secretion pattern was observed;
(iii) remifentanil infusion was associated with lower risk
of atypical sleep compared with normal sleep.
Melatonin secretion pattern has been investigated in several
studies, reporting controversial findings.
Disturbed diurnal variation of melatonin secretion in
critically ill patients was found in several studies [1–3, 11–
13]. Shilo et al. described missing nocturnal top of melatonin
in conscious ICU patients [11]. Frisk et al. found association
of lower 6-SMT (6-sulfatoxymelatonin, the major melatonin
metabolite, measured in urine) excretion with mechanical
ventilation and higher 6-SMT levels associated with benzodi-
azepine sedation, but not with propofol or opioids [12]. Abol-
ished melatonin secretion pattern in sedated mechanically
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Figure 2: Individual melatonin profiles (8 patients, 2 days for each patient). The log-scale of melatonin is used to allow for appreciation of
both interindividual and diurnal variation patterns.
ventilated patients was shown in the study by Olofsson et al.,
but no correlation between levels of sedation and melatonin
levels was found though [3]. Benzodiazepines, opioids and
propofol were used for sedation. Disturbed diurnal pattern
of melatonin secretion was found in sedated critically ill
patients with and without brain injury in the study by Paul
and Lemmer, where serum melatonin levels were lower in
the brain injury group [1]. Benzodiazepines and opioids
were used for sedation. Disturbed circadian rhythmicity of
melatonin secretion was shown in septic patients in two
studies [2, 13]. The majority of patients (5 out of 7) in the
study by Verceles et al. were on mechanical ventilation [13].
Two patients received propofol sedation and one patient was
sedated with dexmedetomidine. All the patients in the sepsis
group in the study by Mundigler et al. were on mechanical
ventilation and sedated with benzodiazepine and opioid [2].
However, preserved diurnal pattern of melatonin secretion
was registered in the group of patients without sepsis in this
study.
Inconsistently with the above-mentioned studies, pre-
served circadian rhythmicity of melatonin secretion in criti-
cally ill patients was described in two studies [4, 14]. Riutta et
al. found maintained diurnal pattern of melatonin secretion
in nonseptic critically ill patients, where 20 out of 40 patients
were on mechanical ventilation and 25 patients were sedated
with benzodiazepines [14]. Benzodiazepines did not affect
diurnal variation of 6-SMT excretion. Collection of twelve-
hour urine samples allowed for assessment of diurnal rhythm
but not the precise timing for 6-SMT excretion. In difference,
Gehlbach et al. measured 6-SMT levels in urine, collected
with hourly intervals, and found preserved circadian rhythm
in the majority of sedated critically ill patients on mechanical
ventilation (13 out of 16), but only 4 patients had normal
timing [4]. Opioids, propofol, and benzodiazepines were
used for sedation. Most subjects exhibited phase-delayed
excretion.There was no difference between patients with and
without sepsis in the proportion of patients with normal
circadian timing.
In line with findings by Gehlbach et al. [4], we observed
phase-delayed diurnal variation of melatonin secretion in
our patients, with acrophase in serum at approximately 4.30
am and nadir at 4.30 pm. Evening light exposure in ICU
due to procedures could probably explain phase-delay in our
patients. Abolished regulation of melatonin secretion by light
and darkness in critically ill patients of different age groups
was described in the study by Perras et al. [15], and the similar
finding is reported in the study by Verceles et al. [13] in
patients with severe sepsis, where light levels were shown
not to entrain circadian rhythm. Critically ill patients with
different levels of consciousness were used in these studies,
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Figure 3: Diurnal variation of sleep and melatonin. Melatonin line represents connected mean melatonin values at each sample point. These
values are standardized to sleep proportion values to visualize both curves on the same scale on 𝑦-axis. Normal sleep (AASM standard) and
atypical sleep (Watson’s classification) are plotted as the proportions of sleep (normal sleep + atypical sleep + wake + undefined = 100%) over
the 24-hour period together with melatonin to visualize diurnal variation of sleep and melatonin.
while all the patients in our study were conscious and able to
open their eyes, and no eyeshades were used. Unfortunately,
we did not register light levels in our study.
In alignment with previous knowledge [16], we found
considerable interindividual variation (64%) and a slight
effect of sex onmelatonin secretion pattern. No age effect was
seen though, probably explained by a small sample size.
The absence of correlation between severities of critical
illness scores with melatonin secretion was mentioned in
some studies [4, 12, 14]. Perras et al. reported APACHE scores
to be negatively correlated with melatonin concentrations in
septic patients but found no correlation in patients without
sepsis [17]. We did not observe any effects of SOFA scores on
melatonin secretion pattern.
The role of sedation related to melatonin secretion is
not completely understood. Different sedative agents were
used in the above-mentioned studies in critically ill patients
showing no clear association between the level of sedation or
the type of sedative agent and melatonin secretion pattern.
Some of the patients in our study were analgosedated with
small doses of remifentanil during the whole or a part of the
study period. We found no significant effect of remifentanil
on melatonin secretion pattern. To our knowledge, this is the
first time melatonin secretion pattern is investigated under
remifentanil infusion in critically ill patients. Nevertheless,
our results are in line with the study by Bonafide et al., where
melatonin secretion was investigated in healthy participants
under sedation with remifentanil and found preserved [18].
The relatively small doses of remifentanil used in both studies
may possibly explain the missing effect of remifentanil on
melatonin secretion.
Graphical exploration of circadian rhythmicity and sleep
in these critically ill patients suggests the presence of
diurnal variation in sleep, phase-delayed compared with
the physiological norm, in the patients with normal sleep
pattern. No rhythmicity or association with melatonin was
seen in the patients with atypical sleep (Figure 3). Due
to the small sample, current data do not allow for a
more rigorous analysis. The potential association between
sleep pattern and the diurnal production of melatonin
ought to be studied in a larger sample of critically ill pa-
tients.
In animal studies, opioids have been described to disrupt
sleep architecture and reduce restorative sleep by affecting
different sleep regulating centers in the brain. Morphine and
fentanyl were found to decrease acetylcholine in pons, the
region regulating REM sleep [5]. Morphine was shown to
affect mu and kappa receptors in ventrolateral preoptic area,
the region primarily responsible for non-REM sleep [19].
However, remifentanil was not found to have the same effect
on acetylcholine as morphine and fentanyl in the study by
Mortazavi et al. [5]. Bonafide et al. investigated the effect of
remifentanil on sleep in healthy humans and found reduced
REM sleep [18]. In line with this study, we only observed
REM sleep in the epochs recorded under the period without
remifentanil.
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Figure 4: Distribution of sleep modes by gender and remifentanil infusion. All the PSG epochs are classified into 4 groups: normal sleep
(AASM standard), atypical sleep (Watson’s classification), awake (wake), and undefined (the epochs with artefacts). The distribution of these
groups by gender and remifentanil infusion at different ages is shown on the graph. The grey field represents confidence intervals.
To our knowledge, the association of remifentanil infu-
sion with the presence of atypical/normal sleep characteris-
tics in PSG in critically ill patients has not yet been studied.
Surprisingly, we found remifentanil to be associated with
lower risk for atypical sleep patterns compared with normal
sleep.The etiology of this finding is unclear and needs further
investigation.
The main weakness of this study is the small number of
patients, since inhomogeneity between patients constitutes
the major source of random variation. This is to some extent
alleviated by multiple measurements on each patient and
thereby allows for detection of diurnal variation of melatonin
secretion.
Melatonin was measured in serum, which is the best
way to estimate circadian function. However, the analysis of
circadian rhythm could be more accurate, if the sampling
intervals were shorter.
We did not measure light levels in the patient rooms
for technical reasons, which is another limitation of this
study.
We found remifentanil infusion to be significantly associ-
ated with an increased proportion of normal sleep. However,
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this study was observational and relatively small doses of
remifentanil were used.
As the sample size was small (8 patients), we did not
account for the admission diagnoses in our statistical anal-
ysis. Despite the variety of diagnoses at admission, all the
patients were conscious, critically ill mechanically ventilated
adults without circulatory failure. Accordingly, we found this
sample to be potentially representative for a specific group of
critically ill patients.
Despite the many limitations, this study reveals some
interesting findings and should therefore be considered
hypothesis-generating. A larger randomized trial to clarify
the influence of remifentanil analgosedation on melatonin
and sleep patterns in critically ill patients is recommended.
The impact of the remifentanil dose ought to be studied as
well. We suggest the registration of light levels as well as
hourly melatonin sampling to be included in the method in
future studies to improve the understanding of the phase-
shift of circadian rhythm. The addition of video recording
to PSG would be useful for the complete assessment of
sleep/wake states in critically ill patients and would allow for
the evaluation of behavioral aspects.
Conclusions. In this pilot descriptive study, melatonin secre-
tion pattern in conscious, critically ill patients on mechanical
ventilation was found to follow a diurnal but phase-delayed
curve. Remifentanil infusion did not affect melatonin secre-
tion but was associated with lower risk of atypical sleep. The
mechanism of this finding is unknown. REM sleep was only
observed in the PSG recordings without remifentanil.
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